Fifteen Years of Work

INTERACTS (INTErventional Radiotherapy ACtive Teaching School) guidelines for quality assurance in choroidal melanoma interventional radiotherapy (brachytherapy) procedures

“…Radiation therapy has gained a major role in the treatment of this disease as described by the COMS (Collaborative Ocular Melanoma Study), which showed no survival differences between patients whose tumors were treated with 125 I eye plaque brachytherapy and those treated with surgical enucleation; however, radiotherapy offers improved visual preservation and cosmetic outcome [4]. Further experiences have confirmed these observations also by the use of different radionuclides ( 106 Ru/Rh or 103 Pd) [5,6,7]. As the size and location of disease have a crucial role in the choice of the clinical management of this tumor, and several aspects should be taken into account, a multidisciplinary approach is strongly suggested [7,8,9,10].…”

INTERACTS (INTErventional Radiotherapy ACtive Teaching School) guidelines for quality assurance in choroidal melanoma interventional radiotherapy (brachytherapy) procedures

“…Radiation therapy has gained a major role in the treatment of this disease as described by the COMS (Collaborative Ocular Melanoma Study), which showed no survival differences between patients whose tumors were treated with 125 I eye plaque brachytherapy and those treated with surgical enucleation; however, radiotherapy offers improved visual preservation and cosmetic outcome [4]. Further experiences have confirmed these observations also by the use of different radionuclides ( 106 Ru/Rh or 103 Pd) [5,6,7]. As the size and location of disease have a crucial role in the choice of the clinical management of this tumor, and several aspects should be taken into account, a multidisciplinary approach is strongly suggested [7,8,9,10].…”

Clinical Outcomes after Surgical Resection Combined with Brachytherapy for Uveal Melanomas

“…Uveal melanoma is the most common primary intraocular malignancy and remains fatal. Currently, brachytherapy, using isotopes of iodine-125 (I-125) and ruthenium-106 (Ru-106), is the most commonly used therapeutic approach for uveal melanoma, with a local control rate in the range of 88-98% at five years [1], and it is equivalent to enucleation in terms of prevention of systemic spread and death [2]. Consequently, plaque brachytherapy remains the method of choice to control primary intraocular tumors [3,4].…”

Modified Geometry of 106Ru Asymmetric Eye Plaques to Improve Dosimetric Calculations in Ophthalmic Brachytherapy

“…Classically, enucleation was the main treatment to achieve local control, although, currently, plaque brachytherapy is the most commonly used treatment for small and medium melanomas, with local control rates of 88–98% at five years [2]. Results are equivalent to enucleation in terms of metastasis free survival and overall survival [3], while having additional benefits, such as better cosmetic results and vision preservation in most of the cases.…”

INTERACTS (INTErventional Radiotherapy ACtive Teaching School) guidelines for quality assurance in choroidal melanoma interventional radiotherapy (brachytherapy) procedures

“…Radiation therapy has gained a major role in the treatment of this disease as described by the COMS (Collaborative Ocular Melanoma Study), which showed no survival differences between patients whose tumors were treated with 125 I eye plaque brachytherapy and those treated with surgical enucleation; however, radiotherapy offers improved visual preservation and cosmetic outcome [4]. Further experiences have confirmed these observations also by the use of different radionuclides ( 106 Ru/Rh or 103 Pd) [5,6,7]. As the size and location of disease have a crucial role in the choice of the clinical management of this tumor, and several aspects should be taken into account, a multidisciplinary approach is strongly suggested [7,8,9,10].…”

Clinical Outcomes after Surgical Resection Combined with Brachytherapy for Uveal Melanomas

“…Uveal melanoma is the most common primary intraocular malignancy and remains fatal. Currently, brachytherapy, using isotopes of iodine-125 (I-125) and ruthenium-106 (Ru-106), is the most commonly used therapeutic approach for uveal melanoma, with a local control rate in the range of 88-98% at five years [1], and it is equivalent to enucleation in terms of prevention of systemic spread and death [2]. Consequently, plaque brachytherapy remains the method of choice to control primary intraocular tumors [3,4].…”

Modified Geometry of 106Ru Asymmetric Eye Plaques to Improve Dosimetric Calculations in Ophthalmic Brachytherapy

“…Classically, enucleation was the main treatment to achieve local control, although, currently, plaque brachytherapy is the most commonly used treatment for small and medium melanomas, with local control rates of 88–98% at five years [2]. Results are equivalent to enucleation in terms of metastasis free survival and overall survival [3], while having additional benefits, such as better cosmetic results and vision preservation in most of the cases.…”

INTERACTS (INTErventional Radiotherapy ACtive Teaching School) guidelines for quality assurance in choroidal melanoma interventional radiotherapy (brachytherapy) procedures

“…Radiation therapy has gained a major role in the treatment of this disease as described by the COMS (Collaborative Ocular Melanoma Study), which showed no survival differences between patients whose tumors were treated with 125 I eye plaque brachytherapy and those treated with surgical enucleation; however, radiotherapy offers improved visual preservation and cosmetic outcome [4]. Further experiences have confirmed these observations also by the use of different radionuclides ( 106 Ru/Rh or 103 Pd) [5,6,7]. As the size and location of disease have a crucial role in the choice of the clinical management of this tumor, and several aspects should be taken into account, a multidisciplinary approach is strongly suggested [7,8,9,10].…”

Clinical Outcomes after Surgical Resection Combined with Brachytherapy for Uveal Melanomas

“…Uveal melanoma is the most common primary intraocular malignancy and remains fatal. Currently, brachytherapy, using isotopes of iodine-125 (I-125) and ruthenium-106 (Ru-106), is the most commonly used therapeutic approach for uveal melanoma, with a local control rate in the range of 88-98% at five years [1], and it is equivalent to enucleation in terms of prevention of systemic spread and death [2]. Consequently, plaque brachytherapy remains the method of choice to control primary intraocular tumors [3,4].…”

Modified Geometry of 106Ru Asymmetric Eye Plaques to Improve Dosimetric Calculations in Ophthalmic Brachytherapy

“…Classically, enucleation was the main treatment to achieve local control, although, currently, plaque brachytherapy is the most commonly used treatment for small and medium melanomas, with local control rates of 88–98% at five years [2]. Results are equivalent to enucleation in terms of metastasis free survival and overall survival [3], while having additional benefits, such as better cosmetic results and vision preservation in most of the cases.…”